BioWorld

Aug. 27, 2002

Alkermes Trims Staff By 23% After Risperdal Consta Delay

The fallout continues at Alkermes Inc., which following a series of recent setbacks reported a 23 percent reduction in its work force. (BioWorld Today) Read More

Bush Insider McClellan Appears To Head FDA Commissioner List

Herpes Infects Mouse Virus To Take On Complement Killers In Acute, Chronic, Latent Infection

Uncertainties Around Finances, Elan Lead Incara To Stop Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...